A cholesterol-lowering drug called inclisiran, sold under the brand name Leqvio, now allows patients to manage dangerously high LDL cholesterol with just two injections per year. Made by Novartis, inclisiran is a small interfering RNA therapy that silences PCSK9 production in the liver, cutting LDL cholesterol by approximately 50 percent in clinical trials. For the millions of older adults who struggle with daily pill regimens or experience statin side effects, this twice-yearly dosing schedule represents a genuine shift in how cardiovascular risk can be managed — and that matters deeply for brain health, since the same vascular damage that leads to heart attacks also contributes to vascular dementia and cognitive decline. What makes inclisiran particularly noteworthy in 2026 is a label expansion the FDA approved in July 2025, allowing the drug to be used as a first-line monotherapy alongside diet and exercise alone, without requiring a statin.
Previously, it was only approved as an add-on for patients already taking statins. This opens the door for people who cannot tolerate statins — a common complaint among older adults — to still achieve dramatic cholesterol reductions. Consider a 68-year-old with mild cognitive impairment and a family history of heart disease who gets muscle pain from every statin she tries: she can now receive two office-based injections per year and cut her LDL nearly in half, potentially protecting both her heart and her brain. This article covers how inclisiran works differently from older PCSK9 inhibitors, what the clinical trial data actually shows over four years, how much it costs and who qualifies for zero-copay programs, and why cholesterol management is increasingly relevant to dementia prevention. We will also look at newer competitors entering the market, including a once-monthly injectable and an oral PCSK9 inhibitor in development.
Table of Contents
- How Does a Twice-Yearly PCSK9 Inhibitor Actually Lower Cholesterol?
- What the Clinical Trials Show — and Where the Evidence Has Limits
- The Cholesterol-Dementia Connection That Makes This Relevant to Brain Health
- What Inclisiran Costs and Who Can Actually Afford It
- Newer Competitors and Why the PCSK9 Landscape Is Shifting
- What Caregivers Should Ask the Doctor Before Starting Inclisiran
- What the ORION-4 Results Could Mean for Dementia Prevention
- Conclusion
- Frequently Asked Questions
How Does a Twice-Yearly PCSK9 Inhibitor Actually Lower Cholesterol?
PCSK9 is a protein your liver produces that breaks down LDL receptors on the surface of liver cells. Fewer LDL receptors means less cholesterol gets pulled out of your bloodstream, so your LDL levels climb. Earlier PCSK9 inhibitors like evolocumab (Repatha) and alirocumab (Praluent) work by sending monoclonal antibodies to block the PCSK9 protein after it has already been made. They require injections every two to four weeks. Inclisiran takes a fundamentally different approach: it uses small interfering RNA to silence the gene that tells the liver to produce PCSK9 in the first place. The protein never gets made, so its effects last far longer per dose. The dosing schedule reflects that durability.
Patients receive a 284 mg subcutaneous injection on day one, a second injection at three months, and then one injection every six months going forward. Importantly, these are administered by a healthcare provider in a clinical setting — patients do not self-inject at home. For someone comparing this to a daily statin pill or even a biweekly self-injection, the practical difference is enormous. A patient with early-stage Alzheimer’s disease who forgets to take daily medications, for example, can have a caregiver simply bring them to two appointments per year and know that their cholesterol management is handled. The distinction between blocking a protein and preventing its production is not just academic. Because inclisiran works at the RNA level, each dose suppresses PCSK9 for months at a time without the peaks and troughs you see with antibody-based therapies. This sustained suppression translates into steady LDL reductions, which may matter for long-term vascular protection in aging brains where consistent blood flow is critical.
What the Clinical Trials Show — and Where the Evidence Has Limits
The pivotal ORION trial program provides the strongest data behind inclisiran. The ORION-9, ORION-10, and ORION-11 trials collectively demonstrated LDL cholesterol reductions of up to 52 percent compared to placebo. These were large, well-designed studies, and the consistency of results across different patient populations — including those with familial hypercholesterolemia and atherosclerotic cardiovascular disease — was encouraging. The ORION-3 open-label extension trial confirmed that these reductions held steady over four years, addressing early concerns about whether the drug’s effect might wane with repeated dosing. When used as a standalone therapy without statins, the results from the V-Mono trial showed a 46.5 percent reduction in LDL cholesterol compared to just 11.2 percent with ezetimibe and 1.4 percent with placebo. That head-to-head comparison with ezetimibe is particularly useful because ezetimibe is the most common non-statin cholesterol drug currently prescribed.
Inclisiran outperformed it by a wide margin. However, there is a critical gap in the evidence that patients and caregivers need to understand. While inclisiran clearly lowers LDL cholesterol, the large cardiovascular outcomes trial — ORION-4, involving roughly 15,000 patients aged 55 and older with existing cardiovascular disease — has not yet reported its primary results. Those are expected around July 2026. An earlier exploratory analysis pooling data from the ORION-9, 10, and 11 trials did show a 26 percent lower probability of major adverse cardiac events with inclisiran versus placebo, but that analysis included only 3,655 patients and was not the trial’s primary endpoint. Until ORION-4 reports, we are relying on the well-established link between LDL reduction and cardiovascular outcomes rather than direct proof from inclisiran-specific event data. If you are considering this drug for a family member with dementia risk, this is worth discussing honestly with their physician.
The Cholesterol-Dementia Connection That Makes This Relevant to Brain Health
The reason a cholesterol drug belongs on a dementia care website is not speculative — it is grounded in decades of vascular research. Vascular dementia, the second most common form of dementia after Alzheimer’s disease, is caused by reduced blood flow to the brain, often from the same atherosclerotic processes that cause heart attacks and strokes. High LDL cholesterol accelerates plaque buildup in the arteries supplying the brain, and midlife cholesterol levels have been linked in longitudinal studies to later-life dementia risk. Managing cholesterol is not just cardiac care; it is brain care. The practical challenge has always been adherence. Studies consistently show that roughly half of patients prescribed statins stop taking them within a year, often due to side effects like muscle pain or simply because a daily pill is easy to forget.
Among older adults with cognitive impairment, adherence rates are even worse. A patient with moderate Alzheimer’s disease living at home may forget their statin three or four days per week, effectively receiving no cardiovascular protection at all. A twice-yearly injection administered in a doctor’s office eliminates the adherence problem entirely. The caregiver books two appointments per year, the injection is given, and there is no daily medication to manage. This matters for mixed dementia as well — the increasingly recognized overlap of Alzheimer’s pathology and vascular damage in the same brain. Even if inclisiran cannot prevent amyloid plaques, reducing the vascular component of cognitive decline is a meaningful intervention. For families already managing the complexity of dementia care, removing one daily medication from the equation while achieving better cholesterol control is not a small thing.
What Inclisiran Costs and Who Can Actually Afford It
The list price of inclisiran is approximately $3,588 per dose, which works out to roughly $7,175 per year for the two maintenance injections. That number sounds prohibitive, and for some patients it will be. But the actual out-of-pocket reality is more nuanced. According to Novartis, about 86 percent of patients currently pay $0 for their inclisiran doses through a combination of the Leqvio Co-Pay Program, Medicaid, Medigap supplemental coverage, or other financial assistance programs. Commercial insurance patients may qualify for the co-pay program that reduces their cost to zero. Compare this to the older PCSK9 inhibitor monoclonal antibodies, which historically carried list prices exceeding $14,000 per year before manufacturer rebates and insurance negotiations brought net costs down.
Inclisiran’s list price is roughly half that, and the co-pay assistance infrastructure is more developed. For Medicare Part B patients, inclisiran is covered as a physician-administered drug — a significant advantage over self-injected medications that fall under Part D and often carry substantial copays. However, coverage is not universal, and prior authorization requirements remain a hurdle. Many insurance plans require documented statin intolerance or failure of other therapies before approving inclisiran. Patients with familial hypercholesterolemia may have an easier path to approval due to established diagnostic criteria. If cost is a concern, the first step is having the prescribing physician’s office contact the Leqvio support program before assuming the drug is unaffordable. The gap between list price and actual patient cost is often dramatic, but navigating insurance bureaucracy takes effort — something that falls on caregivers when the patient has cognitive impairment.
Newer Competitors and Why the PCSK9 Landscape Is Shifting
Inclisiran is no longer the only next-generation option in this space. Lerodalcibep, sold under the brand name Lerochol, received FDA approval on December 15, 2025. It is a third-generation PCSK9 inhibitor dosed once monthly via subcutaneous injection, and it reduces LDL cholesterol by approximately 56 to 60 percent — modestly better than inclisiran’s 50 percent. One practical advantage is that lerodalcibep can be stored at room temperature for up to three months, whereas some biologics require refrigeration. It is expected to be available in the United States by spring 2026. The tradeoff is dosing frequency.
Twelve injections per year versus two is a meaningful difference for elderly patients or those with dementia, even though monthly is still far fewer than the 26 biweekly injections required by older PCSK9 antibodies. For a patient who visits their doctor every month anyway, lerodalcibep might be perfectly manageable. For a patient in a memory care facility where scheduling outside medical appointments is difficult, inclisiran’s twice-yearly schedule has a clear advantage. Perhaps most intriguing is enlicitide, an oral PCSK9 inhibitor currently in Phase 2 trials. Results published in the New England Journal of Medicine and Nature Cardiovascular Research showed a 57.1 percent reduction in LDL cholesterol at 24 weeks with a daily 20 mg oral dose. If this drug reaches the market, it would eliminate the need for injections entirely — but it reintroduces the daily adherence problem that makes inclisiran so appealing for dementia patients. The best option for any given patient will depend on their cognitive status, living situation, caregiver support, and insurance coverage, not just which drug produces the biggest LDL drop on paper.
What Caregivers Should Ask the Doctor Before Starting Inclisiran
If you are a caregiver considering inclisiran for a family member with dementia risk factors or existing cognitive impairment, there are specific questions worth raising at the next cardiology or primary care appointment. Ask whether the patient’s current LDL level and cardiovascular risk profile make them a candidate for PCSK9 inhibition, and whether they have tried and failed or cannot tolerate at least one statin. With the 2025 label expansion, a statin trial is no longer strictly required, but many insurers still want documentation of statin intolerance before covering inclisiran.
Ask about the logistics of the injection visits — whether the primary care office can administer the drug or whether the patient needs to see a specialist. Some cardiology practices have set up dedicated infusion or injection clinics that streamline the process. For a patient with dementia who becomes agitated in unfamiliar medical settings, knowing what to expect and keeping the visit brief matters. Also ask the office to initiate the prior authorization and financial assistance process early, since insurance approvals can take weeks and gaps in dosing are not ideal once the regimen has started.
What the ORION-4 Results Could Mean for Dementia Prevention
The cardiovascular outcomes data from the ORION-4 trial, expected around July 2026, will be the most consequential evidence yet for inclisiran. If the trial demonstrates that sustained PCSK9 silencing with twice-yearly dosing reduces heart attacks, strokes, and cardiovascular death in patients over 55, it will strengthen the case for using inclisiran as a tool for vascular dementia prevention — not just cholesterol management. Stroke prevention alone would be significant, since stroke is one of the strongest risk factors for subsequent dementia.
The broader trend in dementia research is moving toward multi-target prevention strategies that address amyloid, tau, inflammation, and vascular risk simultaneously. Cholesterol management fits squarely into the vascular pillar of that approach. A drug that achieves reliable, sustained LDL reduction with minimal patient burden could become a standard part of dementia risk-reduction protocols, particularly for patients in their 50s and 60s who are still in a window where vascular interventions can make a difference. We will know more when ORION-4 reports, but the logic connecting aggressive LDL lowering to brain health is already well established.
Conclusion
Inclisiran represents a practical advance for patients who need significant cholesterol reduction but struggle with daily medications — a description that fits a large share of the aging population and virtually all patients with moderate to severe dementia. Two injections per year, administered in a medical office, can cut LDL cholesterol by roughly half, and the 2025 label expansion means patients no longer need to be on a statin first. With 86 percent of current patients paying nothing out of pocket, the financial barrier is lower than the list price suggests, though insurance navigation still requires effort. For families managing dementia care, the cardiovascular implications are too important to overlook.
Vascular damage contributes to cognitive decline, and uncontrolled cholesterol accelerates that damage. Whether inclisiran, lerodalcibep, or a future oral PCSK9 inhibitor turns out to be the right fit depends on individual circumstances. But the days of accepting uncontrolled LDL because a patient cannot manage daily pills are over. Talk to a cardiologist or primary care physician about whether twice-yearly PCSK9 inhibition makes sense as part of a comprehensive brain health strategy.
Frequently Asked Questions
Is inclisiran approved for dementia prevention?
No. Inclisiran is FDA-approved for lowering LDL cholesterol in adults with hypercholesterolemia or established cardiovascular disease. Its potential role in dementia prevention is based on the well-documented relationship between cardiovascular health and cognitive decline, not on direct dementia trial data.
Can inclisiran replace statins entirely?
As of the July 2025 label update, inclisiran can be used as a first-line monotherapy with diet and exercise, without requiring a statin. However, some patients benefit from combining both, and insurance plans may still require evidence of statin intolerance before covering inclisiran alone.
How is inclisiran different from Repatha or Praluent?
Repatha (evolocumab) and Praluent (alirocumab) are monoclonal antibodies that block the PCSK9 protein after it is produced, requiring injections every two to four weeks. Inclisiran uses RNA interference to prevent PCSK9 from being produced at all, which is why it works with just two doses per year after the initial loading period.
What are the common side effects of inclisiran?
The most frequently reported side effect in clinical trials was injection site reactions, which were generally mild. Serious adverse events were comparable between inclisiran and placebo groups in the ORION trials. Long-term safety data over four years from ORION-3 has been reassuring, but as with any relatively new drug, ongoing monitoring continues.
Will Medicare cover inclisiran?
Yes, inclisiran is typically covered under Medicare Part B because it is administered by a healthcare provider in a clinical setting. This is different from self-injected PCSK9 inhibitors, which fall under Part D. Part B coverage generally means lower out-of-pocket costs for beneficiaries, though prior authorization may still be required.
Is there an oral PCSK9 inhibitor available?
Not yet. Enlicitide is an oral PCSK9 inhibitor that showed a 57.1 percent LDL reduction in Phase 2 trials, but it has not yet been approved by the FDA. It requires daily dosing, which would reintroduce the adherence challenges that make injectable options like inclisiran attractive for patients with cognitive impairment.
